Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
July 16 2024 - 6:30AM
UK Regulatory
Evaxion Showcases Improved Performance of Key Building Block in
AI-Immunology™ at Computational Biology Conference
- Central AI-Immunology™ Building Block:
Evaxion’s proprietary in-house developed building block, EvaxMHC,
is used across the AI-Immunology™ platform
- Improved Performance: Utilizing a
state-of-the-art novel deep-learning framework as well as training
on public and proprietary data, Evaxion has improved the
performance of EvaxMHC compared to publicly available tools
- Precision in Vaccine Target
Prediction: These advancements in EvaxMHC’s performance
are anticipated to further enhance Evaxion’s ability to accurately
predict vaccine targets
COPENHAGEN, Denmark, July 16, 2024 (GLOBE
NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the
“Company”), a clinical-stage TechBio company specializing in
developing AI-Immunology™ powered vaccines, today showcases
improved performance of its key building block, EvaxMHC, within its
AI-Immunology™ platform, at the 32nd Intelligent Systems
for Molecular Biology (ISMB) conference taking place in Montreal,
Canada, from July 12-16, 2024.
A key feature in developing effective
AI-designed personalized and precision vaccines is the ability to
accurately predict which small fragments, known as peptides, of
pathogens or cancer cells are displayed on the surface of cells by
Major Histocompatibility Complex (MHC) molecules. This display
allows the immune system to recognize and eliminate the threat.
Evaxion’s EvaxMHC building block predicts which peptides are more
likely to be presented by MHC molecules, thereby aiding vaccine
target discovery and facilitating the development of effective
vaccines.
Christian Kanstrup, Evaxion’s CEO, comments:
“Our results demonstrate significant improvements in the prediction
of peptide-MHC interactions, particularly for MHC class II
molecules, which have historically been difficult to predict
accurately. With this advancement on AI-Immunology™ we now have a
more reliable and effective tool for designing personalized and
precision vaccines for cancer and infectious diseases. The improved
EvaxMHC building block is used in the ongoing Phase 2 trial with
Evaxion’s lead vaccine candidate, the personal cancer vaccine
EVX-01.”
Key highlights showcased at the
presentation:
- A state-of-the-art deep-learning framework was utilized,
enhancing the accuracy of peptide-MHC predictions
- Our approach includes three new
strategies: Creating a unified representation for both MHC class I
and -II molecules, utilizing a deep transformer encoder-decoder
architecture, and adopting a generative adversarial network (GAN)
pretraining mechanism
- The updated EvaxMHC building block
led to improved vaccine designs demonstrated in preclinical
studies
About AI-Immunology™
AI-Immunology™ is a scalable and adaptable artificial intelligence
technology platform at the forefront of vaccine discovery for
infectious diseases and cancers. By integrating the collective
power of proprietary AI models PIONEER™, EDEN™, RAVEN™, and
ObsERV™, the platform can model the complexity of the patient’s
immune system. AI-Immunology™ advanced computational modeling
swiftly and uniquely identifies, predicts, and designs vaccine
candidates, revolutionizing the landscape of immunotherapy by
offering a holistic and personalized approach to combat
fast-evolving pathogens and malignant cells.
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its
AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI
prediction models harness the power of artificial intelligence to
decode the human immune system and develop novel immunotherapies
for cancer, bacterial diseases, and viral infections. Based upon
AI-Immunology™, Evaxion has developed a clinical-stage oncology
pipeline of novel personalized vaccines and a preclinical
infectious disease pipeline in bacterial and viral diseases with
high unmet medical needs. Evaxion is committed to transforming
patients’ lives by providing innovative and targeted treatment
options. For more information about Evaxion and its groundbreaking
AI-Immunology™ platform and vaccine pipeline, please visit our
website.
Forward-Looking
Statement
This announcement contains forward-looking
statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. The words “target,” “believe,”
“expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,”
“contemplate,” “continue,” “estimate,” “plan,” “potential,”
“predict,” “project,” “will,” “can have,” “likely,” “should,”
“would,” “could,” and other words and terms of similar
meaning identify forward-looking statements. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various factors,
including, but not limited to, risks related to: our financial
condition and need for additional capital; our development work;
cost and success of our product development activities and
preclinical and clinical trials; commercializing any approved
pharmaceutical product developed using our AI platform technology,
including the rate and degree of market acceptance of our product
candidates; our dependence on third parties including for conduct
of clinical testing and product manufacture; our inability to enter
into partnerships; government regulation; protection of our
intellectual property rights; employee matters and managing growth;
our ADSs and ordinary shares, the impact of international
economic, political, legal, compliance, social and business
factors, including inflation, and the effects on our business
from the worldwide ongoing COVID-19 pandemic and the ongoing
conflict in the region
surrounding Ukraine and Russia and the Middle
East; and other uncertainties affecting our business
operations and financial condition. For a further discussion
of these risks, please refer to the risk factors included in our
most recent Annual Report on Form 20-F and other
filings with the U.S. Securities and Exchange Commission
(SEC), which are available
at www.sec.gov. We do not assume any
obligation to update any forward-looking statements except as
required by law.